FPF
ICPT

FNY Partners Fund’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

FNY Partners Fund’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-253
Closed -$28K – 1246
2017
Q1 		$28K Buy
+253
New +$29.5K ﹤0.01% 872

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FNY Partners Fund's ICPT Position: Q2 2017 in Review

FNY Partners Fund sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2017, closing a stake of 253 shares — an estimated $28K sold.

FNY Partners Fund first reported a position in ICPT in Q1 2017 and held it in 1 quarter. The position peaked at $28K in Q1 2017. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2017.

  • FNY Partners Fund reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • FNY Partners Fund sold 253 Intercept Pharmaceuticals, Inc. shares in Q2 2017, an estimated $28K.
  • FNY Partners Fund first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • FNY Partners Fund's Intercept Pharmaceuticals, Inc. position peaked at $28K in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.